GPX Embolic clinical procedures for tumors and other oncology uses.
Prospective Multicenter GPX® Device Clinical Trial
Clinical Case Examples
‡
Interventional Oncology Use
Embolization of a renal angiomyolipoma (AML) demonstrating targeted delivery and post-treatment tumor shrinkage. The 6-month CT image shows shrinkage of the AML.
Baseline angiogram
DSA post-GPX delivery
CT image of target region 5 days post-treatment
CT image of target region 6 months post-treatment*
Baseline angiogram
Post-embolization angiogram
DSA post-GPX delivery
Pelvic Tumor
Embolization of a pelvic sarcoma illustrating the deep distal reach of the GPX Embolic Device
Explant and Histopathology
Liver tissue explanted 57 days post portal vein embolization demonstrates the durability of GPX Embolic Device
Baseline angiogram
DSA post-GPX delivery
Vessels filled with embolic in explanted tissue (57 days post-embolization) filled with embolic
H&E pathology showing tissue response
_tif.png)
Tumor Devascularization
Right renal tumor successfully embolized with GPX resulting in complete occlusion of the target vessels and resolution of chronic hematuria
Baseline angiogram
Angiogram post-GPX delivery through microcatheter
DSA post-GPX delivery
Renal AML Embolization
Renal angiomyolipoma embolization completed using interventional oncology techniques resulting in complete occlusion of the target vessels
Baseline angiogram
DSA post-GPX delivery
Baseline angiogram
Portal Vein Embolization
Portal vein segment successfully embolized with GPX resulting in a complete cast of a venous system terminal vessel bed and effective occlusion throughout follow-up
Angiogram post-GPX delivery through microcatheter
DSA post-GPX delivery
‡ Data on file. Fluidx Medical Technology, Inc.
* The 6 month CT results fell outside of the trial period.
The GPX Embolic Device is under development and does not have marketing clearance or approval in any market at this time. For investigational use (in New Zealand) only.